In his recent Science article, staff writer Jon Cohen describes screening efforts by multiple teams at multiple companies to look for antibodies against the SARS-CoV-2 S protein.
CoVIC Director Erica Saphire outlines how the CoVIC will use side-by-side in vitro assays and results from in vivo animal models of SARS-CoV-2 infection to define the landscape of S protein antibodies. Each antibody contributed to the CoVIC panel will have a code name, and contributors can gauge how their antibodies perform and use CoVIC data for IND filings. Data from the CoVIC can guide selection of a therapeutic antibody cocktail optimized as a COVID-19 treatment or for prophylaxis in low- and middle-income countries.
